296 related articles for article (PubMed ID: 10137794)
1. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom.
Gross DJ; Ratner J; Perez J; Glavin SL
Health Care Financ Rev; 1994; 15(3):127-40. PubMed ID: 10137794
[TBL] [Abstract][Full Text] [Related]
2. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
3. The pricing of pharmaceuticals: an international comparison.
Dickson M
Clin Ther; 1992; 14(4):604-10; discussion 603. PubMed ID: 1525794
[TBL] [Abstract][Full Text] [Related]
4. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
5. Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry.
Bloor K; Maynard A; Freemantle N
BMJ; 1996 Jul; 313(7048):33-5. PubMed ID: 8664771
[TBL] [Abstract][Full Text] [Related]
6. The market for pharmaceuticals.
Bergenheim K; Braun U
Dev Health Econ Public Policy; 1998; 7():187-208. PubMed ID: 10538829
[No Abstract] [Full Text] [Related]
7. New developments in pricing and drug reimbursement in France.
Pelc A; Castan JP
Pharmacoeconomics; 1994; 6 Suppl 1():28-35. PubMed ID: 10155583
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceuticals. Plunder and pillage.
Earl-Slater A
Health Serv J; 1999 May; 109(5653):18-20. PubMed ID: 10387802
[TBL] [Abstract][Full Text] [Related]
9. Government commitment and regulation of prescription drugs.
Frank RG
Health Aff (Millwood); 2003; 22(3):46-8. PubMed ID: 12757271
[TBL] [Abstract][Full Text] [Related]
10. Dilemmas in regulation of the market for pharmaceuticals.
Maynard A; Bloor K
Health Aff (Millwood); 2003; 22(3):31-41. PubMed ID: 12757269
[TBL] [Abstract][Full Text] [Related]
11. Prescription drugs: issues of cost, coverage, and quality.
Copeland C
EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical policy in Italy: towards a structural change?
Ghislandi S; Krulichova I; Garattini L
Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
[TBL] [Abstract][Full Text] [Related]
13. Prescription-drug prices.
Frank RG
N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
[No Abstract] [Full Text] [Related]
14. Prescription drug prices: why do some pay more than others do?
Frank RG
Health Aff (Millwood); 2001; 20(2):115-28. PubMed ID: 11260933
[TBL] [Abstract][Full Text] [Related]
15. Better pharmaceutical price comparison studies are needed for meaningful evaluation of price-control policies.
Value Health; 2008; 11(1):129-30. PubMed ID: 18179656
[No Abstract] [Full Text] [Related]
16. Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States.
Rodwin MA
Int J Health Serv; 2021 Jul; 51(3):379-391. PubMed ID: 33686883
[TBL] [Abstract][Full Text] [Related]
17. Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.
Kanavos P; Ferrario A; Vandoros S; Anderson GF
Health Aff (Millwood); 2013 Apr; 32(4):753-61. PubMed ID: 23569056
[TBL] [Abstract][Full Text] [Related]
18. The role of economic evaluation in the pricing and reimbursement of medicines.
Drummond M; Jönsson B; Rutten F
Health Policy; 1997 Jun; 40(3):199-215. PubMed ID: 10168752
[TBL] [Abstract][Full Text] [Related]
19. Globalization, pharmaceutical pricing, and South African health policy: managing confrontation with U.S. firms and politicians.
Bond P
Int J Health Serv; 1999; 29(4):765-92. PubMed ID: 10615573
[TBL] [Abstract][Full Text] [Related]
20. Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier?
Sarnak DO; Squires D; Kuzmak G; Bishop S
Issue Brief (Commonw Fund); 2017 Oct; 2017():1-14. PubMed ID: 28990747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
